Please note that we are not able to diagnose, advise, provide acute or chronic care, or make treatment referrals. If you need urgent help, please contact the emergency services or your doctor as soon as possible.
We receive many enquiries about participation in our treatment-resistant depression trial with COMP360 psilocybin therapy. Our phase 2b study has been completed and our study sites do not need any further participants at this time.
We plan to begin a phase 3 trial in 2022. We will provide details of the sites that will be involved once they have been approved. Please note that recruitment to our trial will be managed through our trial sites; we cannot take any names or refer any patients.
For more detail on our trial, click here.
For media inquiries, contact us at email@example.com.